Orange module banner

Learn more about
how donating
plasma works

Donation Process

Green module banner

Hear from the people who benefit from your donations

Patient Stories


At Grifols, our mission is to improve the health and well-being of people around the world

Grifols is a global healthcare company that since its founding in Barcelona in 1909 has enhanced the health and well-being of people around the world. Our four divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop, produce and market innovative solutions and services in more than 100 countries.

As pioneers in the field of plasma science, we are one of the largest plasma companies, with a growing network of donation centers worldwide. We develop this plasma into essential medicines used to treat chronic, rare and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, we also offer a comprehensive portfolio of solutions designed to enhance safety from donation through transfusion. We continue to advance our legacy of innovation by supplying tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with nearly 24,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry.

For more information, please visit


Find a center


Learn about Grifols

Grifols Museum banner


Grifols: A Retrospective History of Innovation

  • Grifols entered the U.S. plasma collection market in 2002 with the purchase of SeraCare, now named Biomat USA, Inc.
  • One year later, Grifols acquired the assets of Alpha Therapeutic Corporation-Mitsubishi, which included a plasma therapy manufacturing plant in Los Angeles.
  • Grifols became the second largest collector of human plasma in the world after acquiring PlasmaCare, Inc., a Cincinnati, Ohio-based plasma collection company in March 2006.
  • The FDA approved a prion-removal method for Grifols products.
  • The FDA approved the first liquid intravenous immune globulin (IGIV) for treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). This is the first IGIV approved to treat this disorder.
  • Grifols acquired Talecris Biotherapeutics Holdings Corp. in June 2011 and became the third-largest global manufacturer of plasma-derived protein therapies. The acquisition enlarged Grifols' plasma collection platform to approximately 150 donor centers across the U.S.
  • PediGri® was implemented, becoming the only program in the industry to offer a comprehensive quality and safety history of each product.
  • Grifols developed the first pasteurized liquid immune globulin in the world. Pasteurization is the most suitable method for eliminating possible pathogens.
  • Grifols incorporated HIV antibody testing of plasma months before it became compulsory.
  • The first double viral-inactivated Factor VIII concentrate in the world was developed. This was treated with solvent/detergent and heat in response to the threat of HIV
  • José Antonio Grífols Lucas became the first researcher to publish significant clinical data on the plasmapheresis technique used to separate plasma from blood and reinject the red blood cells back into the donor. The results of his work were presented at the Congress of the International Society of Blood Transfusion in Lisbon.
  • The plasmapheresis technique provided the means for large-scale plasma collection for manufacturing medicines.
  • Grifols obtained the Spanish patent for freeze-drying plasma and opened one of Europe's first private blood banks.